Eurofins Becomes the Market Leader in Non-invasive Prenatal Testing (NIPT) in Japan With the Acquisition of GeneTech Inc.
07 Août 2020 - 8:30AM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the global scientific leader in
bioanalytical testing and the European leader in non-invasive
prenatal testing (NIPT), announces that it has signed an agreement
with Noritsu Koki Co., Ltd. (7744:JP, Tokyo stock exchange) to
acquire GeneTech Inc. (“GeneTech”), the pioneer in NIPT and a
leading player in genetic analysis in Japan.
GeneTech is the number one player in the NIPT market in Japan
and will provide Eurofins access to its equipment and scientific
expertise, as well as its clients in Asia which includes renowned
specialised medical doctors, major hospitals and clinics. GeneTech
operates a laboratory in the Kazusa DNA Research Institute, a
public research body founded in 1994 that inaugurated its activity
as the world's first institute specialized in DNA-related research.
In addition to its NIPT expertise, GeneTech also has testing
capabilities in preimplantation genetic testing for aneuploidy
(PGT-A) which will expand Eurofins’ testing portfolio in Japan.
GeneTech employs over 35 staff and generated revenues over EUR
10m in 2019. As a result of this acquisition, Eurofins will become
the leader in the NIPT market in Japan with significant scale
advantages over its competitors in the area and will further expand
its global service offering in NIPT.
Notes to Editors:
For more information, please visit www.eurofins.com.
About Eurofins – the global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter
“Eurofins” or “the Group”), believes it is the global leader in
food, environmental, pharmaceutical and cosmetics products testing
and in agroscience CRO services. It is also one of the global
independent market leaders in certain testing and laboratory
services for genomics, discovery pharmacology, forensics, CDMO,
advanced material sciences and in the support of clinical studies.
In addition, Eurofins is one of the leading global emerging players
in esoteric and molecular clinical diagnostic testing. With over
48,000 staff across a network of more than 900 independent
companies in over 50 countries generally specialised by end
client markets and operating more than 800 laboratories,
Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services. The Group’s objective is to provide customers
with high-quality and innovative services, accurate results on time
and, when requested, expert advice by its highly-qualified
staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and a very large
range of testing methods.
As one of the most innovative and quality-oriented international
groups in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the increasing demands of regulatory authorities and healthcare
practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200806006167/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024